Harvard Apparatus Regenerative Technology, Inc. (Nasdaq:HART), or HART,
a clinical stage biotechnology company developing regenerated organs for
transplant, initially focused on the trachea, reports unaudited
financial results for the three and nine months ended September 30, 2014.
PHILADELPHIA, PA --
NEW ORLEANS, LA --
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.